The startup develops cell therapies that target new immune checkpoints and utilize immunomodulation to provide cancer patients with additional treatment options. By focusing on these specific mechanisms, the company aims to enhance patient outcomes and improve the quality of life for those affected by cancer.
Funding
$9.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer immunotherapy faces challenges in effectively targeting tumors due to immune evasion mechanisms and the immunosuppressive tumor microenvironment. Current checkpoint inhibitors have limited efficacy in many patients, highlighting the need for novel targets and strategies to enhance anti-tumor immune responses.
Solution
This startup is developing cell therapies that modulate the immune system to overcome resistance to existing cancer treatments. Their approach focuses on targeting novel immune checkpoints beyond PD-1 and CTLA-4, aiming to reinvigorate exhausted T cells and promote tumor infiltration. By engineering immune cells with enhanced specificity and functionality, the company seeks to create more potent and durable anti-cancer responses. The therapies are designed to reprogram the tumor microenvironment, converting it from immunosuppressive to immunostimulatory, thereby enabling the immune system to effectively eliminate cancer cells.
Target Audience
The primary target audience includes cancer patients who have failed to respond to or have relapsed after standard therapies, as well as oncologists and hematologists seeking innovative treatment options.
Features
- Engineered T cells targeting novel, proprietary immune checkpoints
- Immunomodulatory strategies to enhance T cell activation and persistence
- Reprogramming of the tumor microenvironment to overcome immunosuppression
- Enhanced tumor infiltration and specificity for targeted cancer cells
- Development of allogeneic cell therapies for broader patient accessibility